Can I discontinue lenacapavir PrEP due to its cumbersome dosing schedule, and what alternative PrEP options should I consider?

You Should Not Discontinue Lenacapavir PrEP Based on Dosing Concerns

Lenacapavir's twice-yearly dosing schedule is actually one of the most user-friendly PrEP regimens available, requiring only two injections per year after initial loading—far less burdensome than daily oral medications or bimonthly cabotegravir injections. If you're finding the program interface difficult to navigate, that's a separate technical issue from the medication regimen itself, which is designed specifically to minimize adherence barriers 1.

Understanding Lenacapavir's Actual Dosing Requirements

The dosing schedule consists of:

Initial Loading (Days 1-2):

• Day 1: Two subcutaneous injections (1.5 mL each, at least 4 inches apart) plus two oral tablets
• Day 2: Two oral tablets only 1

Maintenance:

• One injection visit every 6 months (±2 weeks), with two 1.5 mL injections administered at least 4 inches apart 1

This translates to only 2-3 clinic visits per year for injections, compared to 365 days of pill-taking with oral PrEP or 6 injection visits yearly with cabotegravir 2.

Why Lenacapavir Is Superior for Adherence

Lenacapavir demonstrated 100% efficacy in preventing HIV in cisgender women and 96% efficacy in cisgender men, transgender individuals, and gender-nonbinary persons—with zero HIV infections in one trial and only 2 in another 2. This exceptional efficacy is directly linked to its long-acting formulation, which eliminates daily adherence challenges that plague oral PrEP 3, 4.

The evidence shows:

• Adherence to daily oral F/TAF and F/TDF was consistently low in trials, contributing to breakthrough infections 4
• Lenacapavir adherence remained consistently high across diverse populations 5
• The twice-yearly schedule addresses key barriers to PrEP uptake and persistence 6

Alternative PrEP Options (If You Truly Need to Switch)

If you absolutely must discontinue lenacapavir, you must transition to another effective HIV prevention method without interruption 2. Your options include:

Daily Oral PrEP

• Emtricitabine/tenofovir disoproxil fumarate (F/TDF): Most established option, requires daily adherence
• Emtricitabine/tenofovir alafenamide (F/TAF): Alternative with potentially better renal/bone safety profile
• Both require daily pill-taking, which has proven challenging for many populations 4

Long-Acting Injectable Cabotegravir

• Administered every 8 weeks (6 injection visits yearly)
• Requires initial loading with two injections 4 weeks apart, then maintenance every 8 weeks 2
• More frequent than lenacapavir but still superior to daily oral regimens

Critical Transition Considerations

If stopping lenacapavir, you must continue alternative PrEP or use barrier protection for as long as HIV exposure risk continues 2. The long half-life of lenacapavir means drug levels persist, but you cannot rely on residual protection alone.

When switching from lenacapavir to oral PrEP:

• Initiate the oral regimen appropriate for your exposure type
• Continue until HIV exposure risk resolves 2
• If you have hepatitis B, ensure you're not losing HBV treatment by stopping tenofovir-based regimens 1

Common Pitfalls to Avoid

Do not confuse program navigation difficulties with medication burden. Lenacapavir's twice-yearly schedule is objectively less demanding than alternatives. If the issue is:

• Injection site reactions: These occur in ~69% of users but are mostly mild-moderate, diminish over time, and led to discontinuation in only 0.2% of trial participants 1, 2
• Clinic visit logistics: Two visits yearly is still fewer than any other injectable or the quarterly monitoring required for oral PrEP
• Software/portal issues: Contact your provider's technical support—this shouldn't drive clinical decisions

If you discontinue lenacapavir without transitioning to effective alternative prevention, you are at risk for HIV acquisition 2. The background HIV incidence in populations studied was 2.37-2.41 per 100 person-years—lenacapavir reduced this to essentially zero 2, 4.

The Bottom Line

Lenacapavir represents the least burdensome, most effective PrEP option currently available 1, 2, 3, 5. Before discontinuing, carefully distinguish between legitimate medical concerns and technical/logistical issues that can be resolved. If you truly need an alternative, transition immediately to daily oral PrEP or bimonthly cabotegravir—but understand these require significantly more frequent dosing and have demonstrated lower real-world effectiveness due to adherence challenges 4, 6.